Word count: 153 22 Abstract 23 The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) has infected at least 24 1082 people, including 439 fatalities. So far no empirical virus isolation study has been done to 25 elucidate infectious virus secretion as well as serotype variability. Here we used 51 respiratory 26 samples from 32 patients with confirmed MERS-CoV infection for virus isolation in VeroB4 and Caco2 27 cells. We found CaCo2 cells to significantly enhance isolation success over routinely used Vero cells. 28 Isolation success correlated with viral RNA concentration and time after diagnosis, as well as the 29 amount of IgA antibodies secreted in respiratory samples used for isolation. Results from plaque 30 reduction neutralization assays using a representative range of sera and virus isolates suggested that 31 all circulating human MERS-CoV strains represent one single serotype. The choice of prototype strain 32 is not likely to influence the success of candidate MERS-CoV vaccines. However, vaccine formulations 33 should be evaluated for their potential to induce IgA. 34 35
Introduction 36
The Middle East respiratory syndrome (MERS) is an acute respiratory disease first identified in 37 September 2012 in a patient from Jeddah, Kingdom of Saudi Arabia (KSA) (1). It is caused by the 38 MERS coronavirus (MERS-CoV). Infections have directly or indirectly been traced to the Arabian 39 Peninsula in most cases. At least 1082 human cases are known, including 439 fatalities (2). Clinical 40 symptoms include fever, diarrhea, as well as mild to severe respiratory symptoms (3). In spite of a 41 low rate of transmission in the community, hospital outbreaks can reach dramatic extent and cause 42 huge secondary burden on healthcare systems (3, 4) . Data on the infectivity of virus excreted from 43 different body compartments are needed to improve hospital infection control. The few available 44 studies on virus excretion have been limited in size and relied on 6) . However, measuring 45 viral RNA concentration can only provide a surrogate for infectious virus excretion because viral 46 infectivity cannot be measured by pure quantification of viral genomes. Infectivity is additionally 47 determined by cellular and humoral components of the body compartment from which the virus is 48 excreted, such as IgA antibodies. Direct measurement of infectious virus excretion is best 49 accomplished by live virus isolation in cell culture. Systematic virus isolation studies can provide 50 important additional information such as the serotype variability among isolates. Knowledge on viral 51 serotype variability is crucial to determine if antibodies derived from a previous MERS-CoV infection 52 or a potential vaccine can protect from reinfection. The currently circulating viruses are all highly 53 similar to each other in their spike protein, against which most neutralizing antibodies are directed 54 (7, 8) . However, there is a number of other surface proteins that might be targeted by neutralizing 55 antibodies, which is best determined empirically. Here we aimed to study viral infectivity and IgA 56 excretion as well as serotype variability in a sufficiently large number of patients with acute or recent 57
MERS-CoV infection. 58

Patients, Materials and Methods 59
Patients 60 Patients under study were diagnosed with MERS between February and June 2014 at the Prince 61 Sultan Military Medical City (Riyadh, Kingdom of Saudi Arabia). Patient age was 24 to 90 years, with a 62 median of 66 years. Seventy-five% of patients were male. These patients were part of a larger 63 observational, single-centre trial aimed at the determination of virological parameters during MERS-64
CoV infection (4). A regimen to collect, store, and transport original clinical samples under 65 continuous cold chain conditions (storage at -80°C, shipment in dry ice transport containers received 66 intact) was implemented to facilitate a systematic study of virus isolation. A total of 51 samples from 67 32 patients was subjected to virus isolation. From a cross-sectional population-wide serosurvey in 68 KSA, three sera with clear anamnestic MERS-CoV infection were used (9). 69
Virus isolation 70
Five-hundred µL VeroB4 (DSMZ-AC33) cells were seeded per 24 well at 3x10 5 cells/mL in DMEM 71 containing 1% sodium pyruvate, 1% non-essential amino acids, 1% L-glutamine, 1% 72 Penicillin/Streptomycin, and 10% fetal calf serum (FCS; all Gibco®, Darmstadt, Germany) 1 day prior 73 to infection. Caco2 cells (ATCC HTB-37) were used at a concentration of 4x10 5 cells/mL and seeded 2 74 days prior to infection. All patient materials were diluted in 5 mL OptiPRO TM serum-free medium 75 (Gibco®) to reduce viscosity and improve pipetting. Two-hundred µL diluted patient material per 24 76 well were used to inoculate cells for 1 h at 37°C. Afterwards, cells were washed three times with 77 phosphate buffered saline (Gibco®) and supplied with 700 µL fresh medium composite as described 78 above, except for reduced FCS content of 2%, with or without 1% Amphotericin B, and further 79 incubated. Cells were checked daily for cytopathogenic effects. Upon observation of cytopathogenic 80 effects, and otherwise every second day, 50 µL of cell culture supernatant were taken to monitor the 81 increase of MERS-CoV RNA by real-time RT-PCR using the MERS-CoV upE assay as described (10). The 82 supernatant of isolation positive wells was harvested, centrifuged at 200x g for 3 min to remove cell 83 debris, diluted 1:2 in OptiPRO TM (Gibco®) containing 0.5% gelatin for storage, and used to infect 84 VeroB4 cells for the production of virus stocks. All produced virus stocks were quantified by plaque 85 titration 86
Virus strains 87
Virus strains used for plaque reduction neutralization assay were chosen to represent 3 major clades 88 wirthin the MERS-CoV species. Strain Najran-351 represents the Hafr_Al_Batin_1 clade, strain 89
Jeddah-10306 represents clade Riyadh_3, while EMC/2012 is a member of clade A. These clades 90 together cover the whole variability of MERS-CoV as observed in all human cases. 91
Plaque titration and plaque reduction neutralization assay 92
Titration of MERS-CoV was done as described previously (11). VeroB4 cells (3 x 10 5 cells/mL) were 93 seeded 16 h prior to infection with a serial dilution (in OptiPRO TM ) of virus containing medium for 1 h 94 at 37°C. After removing the inoculum, cells were overlaid with 2.4% Avicel (FMC BioPolymers, 95 Brussels, Belgium) 1:2 diluted in 2x DMEM supplemented with 2% sodium pyruvate, 2% non-essential 96 amino acids, 2% L-glutamine, 2% Penicillin/Streptomycin, and 20% FCS. Three days after infection the 97 overlay was discarded, cells were fixed in 6% formaldehyde and stained with a 0.2% crystal violet, 2% 98 ethanol and 10% formaldehyde (all from Roth, Karlsruhe, Germany) containing solution. 99
For plaque reduction neutralization assays 100 µL of a virus solution containing 60 to 80 plaque 100 forming units were incubated with 100 µL diluted patient serum for 1 h at 37°C prior to infection of 101 VeroB4 cells as described above. 102
Recombinant enzyme-linked immunosorbent assay 103
IgA and IgG detection in respiratory tract and serum samples, was done using a recombinant 104 enzyme-linked immunosorbend assay (recELISA; EUROIMMUN AG, Lübeck, Germany) based on the 105 S1 subunit of the MERS-CoV spike protein purified from HEK-293T cells as described elsewhere (12). 106
All samples were diluted 1:100 before applying 100 µL per well and incubation for 30 min at room 107 temperature. Secondary detection was performed using either anti-human-IgA or anti-human-IgG 108 antibodies conjugated with horseradish peroxidase as described in the manufacturer's instructions. 109
Optical density (OD) was measured at 450nm as well as 630nm for background correction with the 110 Synergy 2 Multi-Mode Reader (BioTek, Bad Friedrichshall, Germany). Results are given either in 111 absolute OD (IgA) or as OD ratios determined by dividing individual OD values with a calibrator serum 112 (IgG). 113
Results 114
MERS-CoV isolation from patient material. 115
We studied clinical samples from 32 patients with confirmed MERS-CoV infection who were 116 hospitalized in Riyadh, Kingdom of Saudi Arabia. Initial diagnostic tests had been done by RT-PCR at 117
Riyadh regional laboratory using upE and ORF1A assays as described (10). The clinical courses and 118 their correlation with virological data will be described separately (V.M. Corman, submitted for 119 publication). 120
From those 32 patients whose samples could be stored and shipped under continuous cold chain 121 conditions, all appropriate respiratory samples were subjected to virus isolation attempts in VeroB4 122 cells that are commonly used for cultivation of MERS-CoV. Due to our own preliminary experience 123 we also used the human colon carcinoma cell line Caco2 as an alternative virus isolation cell line. Out 124 of 51 samples from 32 different patients a total of 21 MERS-CoV isolates were obtained. As two 125 patients yielded 2 virus isolates each due to using samples of the same patient taken at different 126 time points, this represented viruses from 19 patients. No virus could be isolated from any of the 4 127 upper respiratory tract samples, while isolation success for the 47 lower respiratory tract samples 128 was 48.6% in endotracheal aspirates and 33.3% in sputa (Fig. 1A) . 129
Only 9 of the 21 MERS-CoV isolates were obtained on VeroB4 cells, the cell line used for isolating the 130 first MERS-CoV strain EMC/2012 (1). In contrast, 20 isolates were obtained in Caco2 cells. There was 131 only one isolate which grew exclusively in VeroB4 cells but 12 which grew exclusively in Caco2 cells. 132
The proportion of successful isolates was significantly superior in Caco2 cells over Vero cells (45.5% 133 vs 19.1%; Fisher's exact test, p = 0.013). The use of Caco cells resulted in a general, sample type-134 independent enhancement of isolation success. 4 of 4 isolates from sputa and 16 of 17 isolates from 135 endotracheal aspirates were grown in Caco cells, while only 1 isolate from sputa and 8 isolates from 136 endotracheal aspirates grew in VeroB4 cells. 137
Factors with potential influence on virus isolation success were analyzed, including viral load in RT-138 PCR, days after initial diagnosis at the time of sampling, as well as IgA antibody titers in respiratory 139 samples used for virus isolation, and IgG antibody titers in patients´ sera from corresponding days. In 140 general, viral load was significantly higher in samples that yielded an isolate than in samples from 141 which isolation failed (t-test, p < 0.0001). There was no significant correlation between viral load and 142 days after diagnosis (Pearson's r = -0.038, p = 0.8). The proportion of successful isolates was 66.7% at 143 RNA concentrations above 10 7 copies per mL, but only 5.9% below this value (Fig. 1B) . In samples 144 taken from patients within 5 days after diagnosis more than half (58.6%) of samples yielded an 145 isolate, while only 22.2% of the samples yielded isolates if taken later (Fig. 1C) . Because the reduced 146 isolation success in later stages of the infection might be a result of rising antibody titers, IgA 147 antibodies in respiratory tract samples used for virus isolation as well as IgG antibodies in sera from 148 the same patient at the same day were determined by recombinant ELISA. The optical density values 149 from IgA and IgG measurements correlated significantly ( Fig. 1D ; Pearson's r = 0.66, p < 0.001). The 150 general level of IgA and IgG was substantially lower in samples yielding an isolate as compared to 151 samples from which isolation failed (t-Test, p = 0.012 and p < 0.001, respectively). 152
MERS-CoV serotype variability 153
Even though it is known that the amino acid variability within the viral spike protein is extremely low 154 between MERS-CoV strains (4), there might be other factors that determine the virus's 155 immunogenicity, which can only be evaluated using replicating virus in neutralization assays. Strains 156 for characterization of viral serotypes were chosen to represent three major phylogenetic lineages of 157
MERS-CoV as defined by Cotton et al. (13). 158
Sera from 3 patients with recent infection (278, 639, 1057) as well as sera from 3 subjects with 159 anamnestic infection (884, 4880, 8692) were selected. The subjects with anamnestic infection were 160 not aware they had overcome MERS-CoV infection. However, they showed unambiguous serological 161 evidence of past MERS-CoV infection in a cross-sectional population-wide serosurvey in KSA (9). Virus 162 strain Najran-351 and serum 639 were obtained from one same patient, providing a matched pair of 163 serum and virus against which all other combinations can be compared. There were no obvious 164 differences in neutralization efficiency, neither between virus strains nor between sera (Fig. 2) . 165
Discussion 166
We have conducted the first study of MERS-CoV infection based on virus isolation, providing 167 information on infectious doses in patient material as well as serotype variability of human MERS-168
CoV strains. We introduce a new and highly sensitive cell culture model for MERS-CoV cultivation and 169 provide for the first time data on secretion of mucosal IgA antibodies against Our data show that isolation of MERS-CoV is most successful when using samples from the lower 171 respiratory tract. This finding is in line with the assumption that MERS-CoV mainly replicates in the 172 lower respiratory tract where it causes severe disease (12, 14) . Caco2 cells should be preferred over 173 other cell lines for isolation of MERS-CoV as they have already been found to enhance isolation 174 success for a number of known respiratory viruses (15). 175 Viral isolation success provided a useful correlate of infectious virus shedding. Next to a clear 176 correlation with RNA concentration, our analyses revealed a decrease of isolation success with longer 177 time into disease. As there was no significant correlation between viral load and time after diagnosis 178 for those samples tested in this study, factors other than RNA concentration might confer an 179 additional influence on the infectivity of clinical samples. One obvious possibility to explain this 180 observation was the presence of anti-MERS-CoV IgA antibodies in respiratory secretions after 181 seroconversion. By adapting an ELISA assay for IgA detection we could confirm that IgA secretion is 182 quantitatively correlated with IgG production in serum, and that presence of IgA indeed influences 183 the rate of successful virus isolation. IgA may have prognostic value if used as a routine diagnostic in 184 MERS-CoV patients, and may influence the potential for re-infection. For instance, it has been 185 described for influenza virus that the level of IgA antibodies in respiratory secretions has influence on 186 infection rates as well as virus-associated illness (16) . As the presence of mucosal IgA might have a 187 more direct influence on the susceptibility against infection with MERS-CoV than serum IgG, IgA 188 production in secretions could be included in regimens to evaluate the potency of candidate vaccines 189 against Using the virus strains isolated in this study we were able to comparatively study the neutralizing 191 ability of individual sera to a representative panel of MERS-CoV strains. We used a sensitive plaque 192 neutralization assay format that identifies even subtle differences in serum neutralization. The use of 193 whole viruses instead of spike-based pseudotype assays ensured that all viral proteins are taken into 194 account in the test. Our studies found no relevant variation between the tested isolates, 195 representing all circulating human MERS-CoV strains. With all sera, the quantitative deviations 196 among tested viruses´ susceptibilities to serum neutralization were insufficient to define more than 197 one distinct serotype because differences in plaque reducing activity were less than 4-fold. Fourfold 198 differences would minimally be expected in different serotypes according to the common definition 199 of significant neutralization titer differences. All of the presently circulating strains would therefore 200 be interchangeable and equivalent for use in candidate vaccine formulations. 201
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